Subscription period in Scandion Oncology Rights Issue of up to approximately SEK 93.7 million commences
The Rights Issue is also open for subscriptions to the public.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE. Scandion Oncology (Scandion or “The Company”), a biotech company developing first-in-class medicines aimed at treating cancer which is resistant to current treatment options,